Assuntos
Lipossomos , Melanose , Extratos Vegetais , Humanos , Melanose/tratamento farmacológico , Extratos Vegetais/farmacologia , Extratos Vegetais/administração & dosagem , Feminino , Resultado do Tratamento , Adulto , Coffea/química , Pessoa de Meia-Idade , Extratos Celulares/farmacologia , Células-Tronco/efeitos dos fármacosAssuntos
Hiperpigmentação , Melanose , Adulto , Humanos , Feminino , Prevalência , Melanose/epidemiologia , FaceRESUMO
BACKGROUND: Clobetasol has demonstrated remarkable results in treating melasma within a short time frame; however, its use is limited because of the risk of local side effects. To date, there is no controlled trial on sequential clobetasol/hydroquinone for melasma. This study aimed to investigate the tolerability and efficacy of 0.05% clobetasol followed by 4% hydroquinone (CLOB-HQ) in comparison to the isolated use of 4% hydroquinone (HQ). METHODS: A double-blinded, randomized clinical trial involving 50 women with facial melasma was performed. They were directed to apply 0.05% clobetasol every night for 14 days, followed by 4% hydroquinone for 46 days (CLOB-HQ group), or the use of hydroquinone for 60 days (HQ group). Evaluations were carried out at inclusion, and after 14 and 60 days of treatment, measuring modified Melasma Area and Severity Index (mMASI), Melasma Quality of Life scale (MELASQoL), and colorimetry. The Global Aesthetic Improvement Scale (GAIS) was assessed by a blinded evaluator. RESULTS: There was no difference in the main outcomes at D14 and D60 (P > 0.1). For CLOB-HQ, the mean (CI 95%) reduction in mMASI was 13.2% (5.1-21.3%) and 43.1% (32.2-54.0%) at D14 and D60, and for HQ, they were 10.6% (5.9-27.5%) and 44.8% (33.2-52.3%). The MELASQoL, colorimetric luminosity, and GAIS showed a progressive improvement for both groups despite no difference between them. No severe side effects were identified. No cases of telangiectasias, atrophy, or perioral dermatitis were associated with the use of CLOB. CONCLUSION: The sequential CLOB-HQ regimen was safe and well tolerated, even though its efficacy was not different from HQ after 14 or 60 days of treatment. Based on these findings, the use of clobetasol 14 days before hydroquinone is not advisable for the treatment of melasma.
Assuntos
Clobetasol , Quimioterapia Combinada , Hidroquinonas , Melanose , Qualidade de Vida , Índice de Gravidade de Doença , Humanos , Hidroquinonas/administração & dosagem , Hidroquinonas/efeitos adversos , Melanose/tratamento farmacológico , Melanose/diagnóstico , Feminino , Método Duplo-Cego , Adulto , Clobetasol/administração & dosagem , Clobetasol/efeitos adversos , Pessoa de Meia-Idade , Dermatoses Faciais/tratamento farmacológico , Esquema de Medicação , Administração Cutânea , Resultado do Tratamento , Fármacos Dermatológicos/administração & dosagem , Fármacos Dermatológicos/efeitos adversosRESUMO
BACKGROUND: Melasma is a chronic dermatosis that impacts the patient's quality of life and can present considerable challenges in terms of effective treatment. OBJECTIVE: To evaluate the effectiveness, tolerability, and safety of 5% cysteamine combined with 4% nicotinamide in female subjects with melasma. METHODS: This single-center, single-arm, prospective, open-label study evaluated patients with melasma using a combination cream of 5% cysteamine and 4% nicotinamide in a progressive regimen (60 min in the first month, 120 min in the second month, and 180 min in the third month). RESULTS: Overall, 35 treated subjects exhibited reduced modified Melasma Area and Severity Index (mMASI) (p < 0.001) and decreased MelasQoL scores (p < 0.001), accompanied by improved brightness, luminosity, homogeneity, and spot intensity (p < 0.001). Photographic and colorimetric analysis revealed smaller spots and improved homogeneity. LIMITATIONS: Adherence to progressive daily treatment could not be evaluated long-term. CONCLUSION: A combination cream comprising 5% cysteamine and 4% nicotinamide was effective, tolerable, and safe for treating melasma.
Assuntos
Cisteamina , Combinação de Medicamentos , Melanose , Niacinamida , Índice de Gravidade de Doença , Adulto , Feminino , Humanos , Pessoa de Meia-Idade , Adulto Jovem , Administração Cutânea , Cisteamina/administração & dosagem , Cisteamina/efeitos adversos , Melanose/tratamento farmacológico , Melanose/diagnóstico , Niacinamida/administração & dosagem , Niacinamida/efeitos adversos , Estudos Prospectivos , Qualidade de Vida , Creme para a Pele/administração & dosagem , Creme para a Pele/efeitos adversos , Resultado do TratamentoRESUMO
PURPOSE: Photobiomodulation therapy (PBM) is a versatile technique for treating skin diseases. Melasma, a chronic hyperpigmentation condition, has recently been associated with vascular features and dermal photoaging and poses significant management challenges. We review the recent literature on melasma etiology and the evidence supporting PBM as a therapeutic modality for melasma treatment. METHODS: We conducted a comprehensive literature search in three different databases from May to August 2023, focusing on studies published in the past 10 years. The inclusion criteria comprised full-text studies investigating low-power lasers and/or light-emitting diodes (LEDs) in in vitro or in vivo models, as well as clinical trials. We excluded studies discussing alternative melasma therapies or lacking experimental data. We identified additional studies by searching the reference lists of the selected articles. RESULTS: We identified nine relevant studies. Clinical studies, in agreement with in vitro experiments and animal models, suggest that PBM effectively reduces melasma-associated hyperpigmentation. Specific wavelengths (red: 630 nm; amber: 585 and 590 nm; infrared: 830 and 850 nm) at radiant exposures between 1 and 20 J/cm2 exert modulatory effects on tyrosinase activity, gene expression, and protein synthesis of melanocytic pathway components, and thus significantly reduce the melanin content. Additionally, PBM is effective in improving the dermal structure and reducing erythema and neovascularization, features recently identified as pathological components of melasma. CONCLUSION: PBM emerges as a promising, contemporary, and non-invasive procedure for treating melasma. Beyond its role in inhibiting melanogenesis, PBM shows potential in reducing erythema and vascularization and improving dermal conditions. However, robust and well-designed clinical trials are needed to determine optimal light parameters and to evaluate the effects of PBM on melasma thoroughly.
Assuntos
Hiperpigmentação , Terapia com Luz de Baixa Intensidade , Melanose , Animais , Terapia com Luz de Baixa Intensidade/efeitos adversos , Melanose/radioterapia , Melanose/complicações , Lasers , Eritema/etiologiaRESUMO
Background/Objectives: Although melasma is highly prevalent, its pathogenesis is not yet fully understood. In the skin, endothelin-1 (ET-1) is primarily produced by keratinocytes in response to UVB exposure, which is mediated by an increase in IL-1α or reactive oxygen species. ET-1 plays a role in melanogenesis by binding to specific receptor B (ERB) or receptor A (ERA). However, the expression of ET-1, ERA, and ERB in melasma has not been systematically investigated. The objective of this study was to evaluate the expression of ET-1, ERA, and ERB in facial melasma compared to the adjacent unaffected skin. Methods: Cross-sectional study, with 40 skin samples (20: facial melasma; 20: adjacent unaffected skin) from women with facial melasma without treatment for 30 days except for sunscreen. A triple staining immunofluorescence technique was performed for anti-vimentin, DAPI, plus one of the following antibodies: (a) anti-ET1, (b) anti-ERA; (c) anti-ERB. Interfollicular areas on the slides of each topography (melasma; unaffected skin) were photographed in triplicate under confocal laser microscopy. The mean staining intensities of the image histograms (0-255 pixels intensity) were estimated for different types of cells (suprabasal keratinocytes, basal layer, and upper dermis) and were blindly compared between topographies. Results: The mean (SD) age of the participants was 44.9 (9.2). The expression of ET-1 was increased in the whole epidermis with melasma when compared to the adjacent skin, being 32.8% (CI95% 14.7%-52.6%) higher in the spinous layer (p=0.013), 30.4% (CI95% 13.7%-47.9%) higher in the basal layer (p=0.014), and 29.7% (CI95% 11.4%-49.7%) higher in the melanocytes (p=0.006). There was no noticeable expression of ET-1 within the cells on the upper dermis. Neither ERA nor ERB resulted in differential epidermal expression between melasma and unaffected skin (p≥0.1). Conclusion: ET-1 is expressed more intensely on the epidermis from the skin with facial melasma compared to the unaffected adjacent skin.
RESUMO
Introducción: El fotoenvejecimiento es una entidad creciente en la consulta de Dermatología, y su comportamiento aparece en edades tempranas de la vida. Esto trae como consecuencia el surgimiento del cáncer cutáneo de forma precoz. Esta afección resulta de la combinación de los efectos del envejecimiento biológico y las consecuencias a largo plazo de la exposición a la radiación ultravioleta, fenómeno que afecta las zonas de la piel expuestas con numerosos cambios morfofisiológicos. Objetivo: Caracterizar el fotoenvejecimiento en pacientes asistidos en consulta de Dermatología. Materiales y métodos: Se realizó un estudio descriptivo, prospectivo en consulta de Dermatología. El universo quedó constituido por 35 pacientes con diagnóstico de fotoenvejecimiento. Se recolectaron las variables en un modelo para este fin. Los resultados se procesaron en tablas para el análisis y discusión de los mismos. Resultados: La mayor frecuencia estuvo entre los 20-30 años y 31-40, con un 37,14 %. El sexo femenino presentó el 91,43 %. Se mostró prevalencia del fotoenvejecimiento grado II, con un 62,86 %, y fotoexposición todo el año, con un 68,57 %. El 74,28 % de los casos fueron trabajadores. Los pacientes con fototipo grados II y III con fotoenvejecimiento grado II, fueron los de mayor porcentaje, con 61,5 % y 56,2 % respectivamente. El 77,3 % tuvo entre 11 y 20 lesiones, y el melasma fue la de mayor incidencia, con 61,54 %. Conclusiones: Las féminas de edad media con fototipo grado III, fotoenvejecimiento grado II, y fotoexpuestas todo el año, mostraron un promedio entre 11 y 20 lesiones, siendo el melasma la más identificada.
Introduction: Photoaging is a growing entity in the Dermatology consultation, and its behavior appears in early ages of life. This results in the onset of precocious skin cancer. This affection results from the combination of the effects of biological aging and the long-term consequences of exposure to ultraviolet radiation, a phenomenon that affects exposed skin areas with numerous morphophysiological changes. Objective: To characterize photoaging in patients treated in Dermatology consultation. Materials and methods: A descriptive, prospective study was carried out in a Dermatology consultation. The universe consisted of 35 patients with diagnosis of photoaging. The variables were collected in a form for this purpose. The results were processed in tables, for their analysis and discussion. Results: The highest frequency was between 20-30 and 31-40 years, with 37.14%. Female sex accounted for 91.43%. It was shown the prevalence of grade II photoaging, with 62.86%, and photo-exposure throughout the year, with 68.75%. 74.28% of cases were workers. The patients with grade II and III phototypes, with grade II photoaging, were the ones with highest percentage, with 61.5% and 56.2% respectively. 77.3% had between 11 and 20 lesions, and melasma had the highest incidence, with 61.54%. Conclusions: Middle-aged women, with grade III photo-type, grade II photoaging, and photoexposure throughout the year, showed an average of between 11 to 20 lesions, melasma being the most identified.
RESUMO
Introducción: El melasma facial consiste en una hiperpigmentación que se origina por un incremento de la melanina epidérmica o dérmica, o ambas, y se localiza en las áreas fotoexpuestas, lo cual afecta, en ocasiones, la autoestima de hombres y mujeres. Objetivo: Evaluar la efectividad del tratamiento con láser de helio-neón en pacientes con melasma facial. Métodos: Se realizó un estudio cuasiexperimental de intervención terapéutica en 34 pacientes con diagnóstico clínico y dermatoscópico de melasma facial, atendidos en la consulta de dermatología del Hospital General Docente Dr. Juan Bruno Zayas Alfonso en Santiago de Cuba, de enero del 2019 a igual mes del 2020, para lo cual se conformaron dos grupos: uno de estudio, que recibió tratamiento con láser, y el otro de control, tratado con crema de hidroquinona a 2 %. La información fue procesada y resumida en valores absolutos y porcentaje; asimismo, se utilizó la prueba paramétrica de homogeneidad de la Χ2, con un nivel de significación α=0,05. Resultados: En general, la mayoría de los pacientes correspondieron al grupo etario de 39-48 años (35,3 %) y al sexo femenino (82,3 %), tenían color de la piel mestizo (76,5 %) y lesiones de tamaño mediano (58,8 %). Si bien no existieron diferencias estadísticamente significativas entre las respuestas terapéuticas de cada grupo de estudio, en los pacientes tratados con láser de helio-neón la mejoría clínica fue evidente a los 3 meses de finalizada la intervención (70,6 %). Conclusiones: El tratamiento con láser de helio-neón fue efectivo en los pacientes con melasma.
Introduction: Melasma is a hyperpigmentation caused by an increase in epidermal or dermal melanin concentration, or both, and it is located on photoexposed cutaneous regions. It affects sometimes men's and women's self-esteem. Objective: To evaluate the effectiveness of helium-neon laser treatment in patients with melasma. Methods: A quasi-experimental study of therapeutic intervention in 34 patients with clinical and dermoscopic diagnosis of melasma, who were assisted at the Dermatology Service of Dr. Juan Bruno Zayas Alfonso Teaching General Hospital in Santiago de Cuba was carried out from January, 2019, to the same month in 2020, for which two groups were formed: the study group, that received laser treatment, and the control group, treated with 2% hydroquinone cream. The information was processed and expressed in absolute values and percentage; likewise, the Χ2 test for homogeneity was used, with a significance level of α=0.05. Results: In general, most of the patients belonged to 39-48 age group (35.3%) and were female (82.3%), with mixed skin color (76.5%) and medium-sized lesions (58.8%). Although there were no statistically significant differences between the therapeutic responses of each study group, clinical improvement in patients treated with helium-neon laser was evident 3 months post-intervention (70.6%). Conclusions: Helium-neon laser treatment was effective in patients with melasma.
RESUMO
Abstract Background: In addition to melanocytic hyperfunction, changes are observed in the upper dermis of melasma, and fibroblasts play a central role in collagen synthesis and pigmentation induction. Objective: To explore the morphology, growth rate, and gene expression profile of fibroblasts from the skin with melasma in comparison to fibroblasts from the adjacent healthy skin. Methods: Ten women with facial melasma were biopsied (lesion and adjacent healthy skin), and the fragments were processed for fibroblast culture. Samples from five participants were seeded to evaluate growth (days 2, 5 and 8) and senescence (SA-β-gal) curves. The samples from the other participants were submitted to real-time PCR to comparatively evaluation of the expression of 39 genes. Results: Cultured fibroblasts from melasma skin were morphologically less fusiform in appearance and on average a 34% (95% CI 4%-63%) greater proportion of cells labeled with SA-β-gal than the fibroblasts from the adjacent skin. The cell growth rate was lower for the melasma samples after eight days (p < 0.01). The WNT3A, EDN3, ESR2, PTG2, MMP1, and SOD2 genes were up-regulated, whereas the COL4A1, CSF2, DKK3, COL7A1, TIMP4, CCL2, and CDH11 genes were down-regulated in melasma skin fibroblasts when compared to the ones from adjacent healthy skin. Study limitations: Small sample size; absence of functional tests. Conclusions: Fibroblasts from the skin with melasma showed a lower growth rate, less fusiform morphology and greater accumulation of SA-β-gal than those from adjacent photo exposed skin. Moreover, their gene expression profile comprised factors that may contribute to upper dermis damage and sustained melanogenesis.
RESUMO
BACKGROUND: Melasma is an acquired hyperpigmentation disorder. Microneedling is an alternative treatment for melasma especially by improving penetration of pharmacological agents into the skin. OBJECTIVE: The main objective of this review was to systematize and analyze available evidence on the efficacy and safety of microneedling alone or associated with topical agents in reducing skin stains and improving melasma-related quality of life in adult patients. METHODS: Only randomized clinical trials were included. The following databases were consulted: MEDLINE, Embase, Cochrane, and the gray literature. The Cochrane risk-of-bias tool for randomized trials (RoB 2.0) was used to assess risk of bias. RESULTS: The search retrieved 719 records and seven studies were included. A total of 368 participants (96.19% women) were evaluated. Two studies were split-face. Most of the studies evaluated microneedling associated with tranexamic acid. High risk of bias was presented by most studies, especially in the safety outcome. A significant decrease was observed in the MASI, mMASI, or hemi-MASI scores, regardless of the topical agents associated. Meta-analysis was not possible due to the heterogeneity of the studies. CONCLUSION: Based on the results of this review, microneedling can, in association with topical agents or isolated, be used safely in the treatment of melasma in the clinical practice, obtaining results on reduction of stain severity and improvement of patients' quality of life.
Assuntos
Hiperpigmentação , Melanose , Ácido Tranexâmico , Adulto , Humanos , Feminino , Masculino , Qualidade de Vida , Administração Cutânea , Melanose/tratamento farmacológico , Hiperpigmentação/tratamento farmacológico , Terapia Combinada , Resultado do TratamentoRESUMO
Melasma is a common circumscribed hypermelanosis of sun-exposed areas of the skin. Platelet-Rich Plasma therapy has been evidenced to inhibit melanin synthesis in animals and humans. To determine the effectiveness of platelet-rich plasma as a treatment for melasma. Twenty female patient with melasma were involved in this study. The intervention included three Platelet-Rich Plasma application sessions at 15-day intervals. Patients were evaluated before and after treatment. Variables measured included the facial melanin concentration using the melasma area and severity index score, melasma quality of life scale satisfaction grade, and histologic changes. Mean age was 41 ± 7 years. An initial MELASQOL score of 42 ± 14.8 and final score of 16.6 ± 7.2 (p = 0.008) were reported; the initial and final MASI score were 15.5 ± 8.4 and 9.5 ± 7.2 (p = 0.001), respectively. The dermatoscopy examination revealed a decrease in pigmentation after intervention (p = 0.001). Histopathologic improvement was detected in reductions in cutaneous atrophy (14 [70%] vs. 11 [55%]), solar elastosis (15 [75%] vs.11 [55%]), and inflammatory infiltrate (9 [45%] vs. 6 [30%]), before and after treatment, respectively. The intervention was associated with decreased intensity of the melasma patch and improved skin quality, shown by the MELASQOL and MASI scores.
Assuntos
Melanose , Plasma Rico em Plaquetas , Adulto , Feminino , Humanos , Melaninas/uso terapêutico , Melanose/tratamento farmacológico , Pessoa de Meia-Idade , Qualidade de Vida , Resultado do TratamentoRESUMO
BACKGROUND: In addition to melanocytic hyperfunction, changes are observed in the upper dermis of melasma, and fibroblasts play a central role in collagen synthesis and pigmentation induction. OBJECTIVE: To explore the morphology, growth rate, and gene expression profile of fibroblasts from the skin with melasma in comparison to fibroblasts from the adjacent healthy skin. METHODS: Ten women with facial melasma were biopsied (lesion and adjacent healthy skin), and the fragments were processed for fibroblast culture. Samples from five participants were seeded to evaluate growth (days 2, 5 and 8) and senescence (SA-ß-gal) curves. The samples from the other participants were submitted to real-time PCR to comparatively evaluation of the expression of 39 genes. RESULTS: Cultured fibroblasts from melasma skin were morphologically less fusiform in appearance and on average a 34% (95% CI 4%â63%) greater proportion of cells labeled with SA-ß-gal than the fibroblasts from the adjacent skin. The cell growth rate was lower for the melasma samples after eight days (p < 0.01). TheWNT3A, EDN3, ESR2, PTG2, MMP1, and SOD2 genes were up-regulated, whereas the COL4A1, CSF2, DKK3, COL7A1, TIMP4, CCL2, and CDH11 genes were down-regulated in melasma skin fibroblasts when compared to the ones from adjacent healthy skin. STUDY LIMITATIONS: Small sample size; absence of functional tests. CONCLUSIONS: Fibroblasts from the skin with melasma showed a lower growth rate, less fusiform morphology and greater accumulation of SA-ß-gal than those from adjacent photo exposed skin. Moreover, their gene expression profile comprised factors that may contribute to upper dermis damage and sustained melanogenesis.
Assuntos
Melanose , Colágeno Tipo VII , Feminino , Fibroblastos , Expressão Gênica , Humanos , Melanócitos , PeleRESUMO
Melasma is a multifactorial dyschromia that results from exposure to external factors (such as solar radiation) and hormonal factors (such as sex hormones and pregnancy), as well as skin inflammation (such as contact dermatitis and esthetic procedures), in genetically predisposed individuals. Beyond hyperfunctional melanocytes, skin with melasma exhibits a series of structural and functional alterations in the epidermis, basement membrane, and upper dermis that interact to elicit and sustain a focal hypermelanogenic phenotype. Evolution in the knowledge of the genetic basis of melasma and the cutaneous response to solar radiation, as well as the roles of endocrine factors, antioxidant system, endothelium proliferation, fibroblast senescence, mast cell degranulation, autophagy deficits of the melanocyte, and the paracrine regulation of melanogenesis, will lead to the development of new treatments and preventive strategies. This review presents current knowledge on these aspects of the pathogenesis of melasma and discusses the effects of specific treatments and future research on these issues.
RESUMO
Melasma is a prevalent chronic relapsing pigmentary disorder that affects photoexposed areas, especially in women of childbearing age. Although there is currently no curative treatment available for melasma, this manuscript critically reviews the knowledge regarding photoprotection, topical and oral therapies, and procedures such as peelings, laser, and microneedling that represent the main strategies for control and prevention of this disease. As the pathogenesis of melasma is not entirely understood, there are prospects for the development of new therapeutic strategies that might act on the pathways that promote sustained pigmentation rather than merely decreasing melanin synthesis and removing melanin from the epidermis.
RESUMO
BACKGROUND: Melasma is a common hypermelanosis characterized by symmetrical brownish macules, especially on the face. Histologic analysis demonstrates increased epidermal and dermal melanin. Dermoscopy is useful to estimate the depth of the melanin and may help in the diagnosis and classification of melasma, with therapeutic importance. OBJECTIVES: To evaluate the diagnostic concordance of dermoscopic classification of epidermal or mixed subtypes of melasma and the correlation between dermoscopic and histopathological findings. METHODS: Twenty-eight women with facial melasma, phototypes III to V, ages between 30 and 61 years were selected. Based on the evaluation of clinical and dermoscopic images, two independent observers classified melasma into epidermal or mixed subtypes. The intra and interobserver concordances were calculated. Histopathological analysis of epidermal melanin extension and maximum number of melanophages per high-power field (400×; HPF) have been assessed. Association between the melanophages count and the dermoscopic classification was evaluated. RESULTS: Intraobserver agreement was 82.1%, and between observers, from 78.6% to 89.3%, according to the Kappa index. Histopathology revealed increased intraepidermal melanin and the presence of dermal melanophages in all the samples. Ten or more melanophages/HPF was significantly associated with mixed melasma. CONCLUSIONS: Moderate to substantial concordance in the dermoscopic classification of melasma was found, and the correlation between this classification and the dermal melanophages count have been suggested. Intradermal component of every case of melasma should be considered for therapeutic and prognostic purposes.
Assuntos
Hiperpigmentação , Melanose , Humanos , Feminino , Adulto , Pessoa de Meia-Idade , Melaninas , Melanose/tratamento farmacológico , Epiderme/diagnóstico por imagem , Epiderme/patologia , Hiperpigmentação/patologia , DermoscopiaRESUMO
Objective: We conducted a review of topical agents currently used in melasma, discussing their mechanism of action, efficacy, safety, and tolerability, with an update on newer treatments. Methods: A systematic review from PubMed database was performed, using PRISMA guidelines. The search was limited to English and Spanish studies that were double or single blinded, prospective, controlled or randomized clinical trials, reviews of literature, and meta-analysis studies. Results: 348 studies were analyzed; 80 papers met inclusion criteria. Triple combination (TC) therapy and hydroquinone (HQ) are still the most well-studied agents with strong evidence-based recommendation. TC therapy remains the gold standard of care based on efficacy and patient tolerability. Evidence has shown ascorbic acid, azelaic acid, glycolic acid, kojic acid, salicylic acid, and niacinamide to be effective as adjuvant therapies with minimal side effects. Tranexamic acid (TA) and cysteamine have become recent agents of interest due to their good tolerability, however more trials and studies are warranted. Less evidence exists for other topical agents, such as linoleic acid, mulberry extract oil, rucinol, 2% undecylenoyl phenylalanine, and epidermal growth factors agents. Limitations: Some studies discussed represented a low sample size, and there is an overall lack of recent studies with larger populations and long-term follow up. Conclusions: TC therapy continues to be the gold standard of care. Topical cysteamine and TA are newer options that can be incorporated as adjuvant and maintenance treatments into a patient's regimen. Cysteamine and topical TA have no known severe adverse effects. Evidence comparing other topical adjuvant treatments to HQ, maintains HQ as the gold standard of care.
RESUMO
OBJECTIVE: To compare the psychometric performance of a generic and specific instruments in assessing melasma-related quality of life. METHODS: A cross-sectional study was conducted with 150 patients with melasma attending an outpatient dermatology clinic of a public hospital in São Paulo state, Brazil. Data were collected using a questionnaire containing sociodemographic and clinical data as well as the generic WHOQOL-BREF, and the dermatological-specific Skindex-16 and HRQ-Melasma. RESULTS: The overall internal consistency of the domains of the three instruments was ≥ 0.7. A strong positive correlation was identified between the Skindex-16 and HRQ-Melasma domains (0.68-0.78). Item-response theory showed that most Skindex-16 and HRQ-Melasma domains were more informative than WHOQOL-BREF. CONCLUSION: The three instruments for assessing QOL tested presented good psychometric performance, with satisfactory internal consistency values. Only the two dermatological instruments, however, demonstrated a strong correlation between the domains that assess social, emotional, and functional aspects of QOL, indicating that both were able to identify impairments in other QOL dimensions in addition to the physical domain.
Assuntos
Melanose , Qualidade de Vida , Brasil , Estudos Transversais , Humanos , Melanose/psicologia , Psicometria , Qualidade de Vida/psicologia , Reprodutibilidade dos Testes , Inquéritos e QuestionáriosRESUMO
Background Melasma is an acquired dyschromia with several histologic alterations in the epidermis, basement membrane and upper dermis. The treatment of melasma is challenging due to the irregular response and chronicity of the disease. To date, there are no curative strategies, largely due to the limited understanding of the intrinsic effects of each treatment. Objectives The objective of the study was to evaluate the histological changes promoted by triple combination cream, with or without complementary treatment with microneedling and oral tranexamic acid, in the treatment of melasma. Methods A factorial, randomised, controlled and evaluator-blinded clinical trial was performed involving 64 women with facial melasma, divided in four groups, who underwent 60 days of treatment with triple combination cream alone (control group) or combined with two monthly microneedling sessions (microneedling group), TA 250 mg twice daily (tranexamic acid group), or both tranexamic acid group and microneedling group. The participants underwent biopsy of the area with melasma at inclusion (D1) and D60. The primary outcomes were the variation (D1 × D60) between the variables: Thickness of the epidermis and stratum corneum, stratum corneum compaction and solar elastosis; melanin density in the epidermis and upper dermis; proportion between the extension of the nonintact and intact basement membrane zone; mast cell count in the upper dermis; melanocyte count in the basal layer, pendulum melanocyte count and melanocyte area; immunostaining density of vascular endothelial growth factor; stem cell factor and keratinocyte growth factor. Results One participant in the TG discontinued tranexamic acid due persistent headache; and herpes simplex occurred in three patients after microneedling. The groups showed a 24% (CI95%: 17-35%; P < 0.01) reduction in epidermal melanin density. There was no change in dermal melanin density or the area of melanocytes after treatment. There was an overall 25% (CI95%: 7-42%; P < 0.01) reduction in the number of pendulum melanocytes, especially in the microneedling and tranexamic acid group, that presented a 41% (CI95%: 7-73%; P < 0.01) reduction. The extension of the nonintact basal membrane relative to the intact basal membrane decreased after treatment, especially in microneedling group and microneedling and tranexamic acid group. There was an increase of 13% (CI95%: 5-21%; P = 0.02) in epidermal thickness and 6% (CI95%: 0-22%; P = 0.04) thinning of the stratum corneum in the groups. All groups showed stratum corneum compaction. Solar elastosis improved only in the microneedling group and microneedling and tranexamic acid group. Vascular endothelial growth factor immunostaining increased 14% (CI95%: 4-24%; P = 0.03) in the groups; and stem cell factor increased only in microneedling group. There was no change in the number of mast cells, CD34 and keratinocyte growth factor immunostaining. Limitations The site of biopsy may not represent all of the facial melasma and the immunohistochemical sensitivity of the cytokines does not have a stoichiometric relationship with proteins. Conclusion A greater thickness of the epidermis is associated with melasma bleaching. Dermal melanin seems to have no impact on melasma prognosis. Damage to the skin barrier and stimulus of angiogenesis should be avoided in the treatment of melasma. Microneedling complements the topical treatment of melasma by improving patterns of skin photoaging. Oral tranexamic acid complements the topical treatment of melasma by inhibiting the stem cell factor.
Assuntos
Melanose , Ácido Tranexâmico , Humanos , Feminino , Fator 7 de Crescimento de Fibroblastos/uso terapêutico , Melaninas , Fator A de Crescimento do Endotélio Vascular , Fator de Células-Tronco/uso terapêutico , Melanose/terapia , Melanose/tratamento farmacológico , Resultado do TratamentoRESUMO
BACKGROUND: Melasma is an acquired pigmentation disorder with a complex multifactorial etiopathogenesis. Oral tranexamic acid (TA) is a promising drug for its treatment and may enhance outcomes when used in combination. OBJECTIVE: To provide evidence of the efficacy and safety of oral TA as a monotherapy, and in combination with a triple combination cream, for treating melasma in the Hispanic population. METHODS: Forty-four female Hispanic patients with melasma were randomly assigned to receive 325 mg of oral TA every 12 h plus f-TCC (fluocinolone-based triple combination cream) every 24 h (group A) or 325 mg of oral TA every 12 h (group B) for 8 weeks, after which both groups were crossed-over, and treated for an additional 8 weeks. Evaluations of the mMASI score, the melanin index, and the MelasQoL were made at baseline and Weeks 4, 8, 12, and 16. RESULTS: There was a 50.04% and 65.45% improvement in mMASI at Weeks 4 and 8, respectively, in group A, compared to baseline, while for Week 16, an improvement of 76.85% was achieved in group B compared to baseline. Highest scores were consistent with the use of the combined treatment modality in both groups, and were evidenced by the values of the melanin index obtained. There was no significant difference in MelasQoL scores between the 2 groups. No serious side effects were observed. CONCLUSION: The combination of oral TA and f-TCC is more effective than oral TA alone in the treatment of severe melasma in Hispanic patients.